Your browser is no longer supported. Please, upgrade your browser.
ASLAN Pharmaceuticals Limited
Index- P/E- EPS (ttm)-0.44 Insider Own- Shs Outstand69.29M Perf Week-29.80%
Market Cap146.89M Forward P/E- EPS next Y-0.40 Insider Trans- Shs Float47.93M Perf Month-21.48%
Income-21.30M PEG- EPS next Q-0.12 Inst Own40.10% Short Float2.89% Perf Quarter-38.90%
Sales- P/S- EPS this Y70.90% Inst Trans0.89% Short Ratio1.11 Perf Half Y-39.26%
Book/sh1.08 P/B1.96 EPS next Y14.90% ROA-37.50% Target Price- Perf Year13.37%
Cash/sh1.36 P/C1.56 EPS next 5Y- ROE-63.80% 52W Range1.42 - 6.75 Perf YTD15.85%
Dividend- P/FCF- EPS past 5Y60.00% ROI- 52W High-71.33% Beta2.30
Dividend %- Quick Ratio18.50 Sales past 5Y- Gross Margin- 52W Low36.27% ATR0.27
Employees18 Current Ratio18.50 Sales Q/Q- Oper. Margin- RSI (14)27.55 Volatility10.17% 7.86%
OptionableYes Debt/Eq0.21 EPS Q/Q25.30% Profit Margin- Rel Volume4.87 Prev Close2.12
ShortableYes LT Debt/Eq0.20 Earnings- Payout- Avg Volume1.25M Price1.93
Recom2.00 SMA20-35.47% SMA50-32.08% SMA200-35.13% Volume3,401,781 Change-8.73%
Jul-09-21Initiated Jefferies Buy $8
Jan-14-19Reiterated H.C. Wainwright Buy $12 → $8.50
Sep-28-21 10:11AM  
Sep-27-21 02:30PM  
Sep-22-21 07:00AM  
Sep-21-21 07:00AM  
Sep-13-21 08:38AM  
Sep-09-21 07:00AM  
Aug-06-21 07:00AM  
Aug-04-21 07:00AM  
Jul-27-21 10:38PM  
Jul-13-21 07:00AM  
Jul-09-21 06:08PM  
Jun-14-21 07:11AM  
Jun-08-21 09:04AM  
Jun-04-21 09:04AM  
May-25-21 07:30AM  
May-11-21 07:30AM  
May-07-21 07:24AM  
May-05-21 05:22AM  
Apr-30-21 09:24AM  
Apr-22-21 07:51AM  
Apr-14-21 09:38AM  
Mar-18-21 07:27AM  
Mar-10-21 12:00PM  
Mar-04-21 02:47PM  
Mar-03-21 12:42AM  
Mar-02-21 08:01AM  
Mar-01-21 04:01PM  
Feb-25-21 06:30AM  
Feb-18-21 07:00AM  
Jan-27-21 07:35AM  
Jan-26-21 07:30AM  
Jan-11-21 05:34AM  
Jan-08-21 09:57AM  
Jan-06-21 11:13AM  
Jan-04-21 09:34AM  
Dec-30-20 11:25AM  
Dec-25-20 12:00PM  
Dec-23-20 10:06AM  
Dec-22-20 10:27AM  
Dec-21-20 10:13AM  
Dec-10-20 09:40AM  
Dec-03-20 10:04AM  
Dec-02-20 06:03PM  
Dec-01-20 10:06AM  
Nov-29-20 08:24PM  
Nov-27-20 08:25AM  
Nov-24-20 03:10PM  
Nov-19-20 07:22AM  
Nov-18-20 11:24AM  
Nov-16-20 06:30AM  
Nov-09-20 07:00AM  
Oct-22-20 07:30AM  
Oct-19-20 10:05AM  
Oct-16-20 05:25AM  
Sep-21-20 06:00AM  
Sep-10-20 03:08AM  
Aug-24-20 03:27AM  
Aug-07-20 03:00AM  
Jul-17-20 06:08AM  
Jul-13-20 12:00PM  
Jun-25-20 08:50AM  
Jun-19-20 05:50PM  
Jun-11-20 12:00PM  
Jun-04-20 09:46PM  
May-11-20 05:34AM  
May-07-20 05:50PM  
Apr-20-20 08:56AM  
Apr-13-20 04:21AM  
Mar-26-20 12:00PM  
Mar-18-20 05:18AM  
Feb-24-20 02:05AM  
Feb-20-20 05:50PM  
Feb-10-20 05:45PM  
Feb-04-20 05:45PM  
Jan-28-20 10:39AM  
Jan-27-20 11:30AM  
Jan-15-20 04:34PM  
Jan-14-20 08:53AM  
Jan-13-20 12:00PM  
Jan-06-20 12:04PM  
Dec-18-19 09:58AM  
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.